Quick Facts

• Relief of Symptoms Associated with Fungal Infections: Assists in managing discomfort and irritation.
• Management of Common Dermatophyte Infections: Used to address conditions such as ringworm, jock itch, and athlete's foot.
• Addressing Yeast-Related Conditions: May be prescribed for the topical management of cutaneous candidiasis (skin yeast infections).

---

What Antifungol Treats: Main Uses and Benefits

Antifungol is an agent generally utilized in the care and management of superficial fungal infections. Its use is indicated for a range of common skin conditions caused by dermatophytes and yeasts. The medication assists in providing relief from associated symptoms, such as itching, scaling, and inflammation, contributing to the resolution of the affected area.

In the category of dermatophyte infections, Antifungol is a therapeutic option for tinea infections, which include athlete's foot (tinea pedis), ringworm of the body (tinea corporis), and jock itch (tinea cruris). These conditions are common and involve the outer layers of the skin, hair, and nails. Its use is also relevant for certain yeast infections, specifically for managing cutaneous candidiasis, which is a yeast overgrowth on the skin.

Antifungol is an established intervention that offers therapeutic value by limiting the proliferation of the causative organism. The objective of treatment is to achieve clinical improvement in the skin condition. The use of an antifungal is a core component in the therapeutic regimen for these mycoses.

Regulatory References

1. NIH MedlinePlus guidance on common fungal infections

Who Can and Cannot Use Antifungol?

Eligibility for Antifungol (clotrimazole topical and vaginal formulations) is determined by regulatory authorities based on specific contraindications and population status.

---

Eligibility Scope

Category	Regulatory Status (Strictly Label-Based)
Populations for whom use is allowed	Adults and adolescents are the standard populations for approved use.
Populations for whom use is contraindicated	Individuals with a known hypersensitivity or allergy to clotrimazole or any component of the formulation are absolutely prohibited from use.
Age-related eligibility rules	Safety and effectiveness are not established for unsupervised use in children under 12 years of age for many non-prescription indications. Safety and efficacy in children for approved indications have been established in certain formulations.
Pregnancy and lactation eligibility status	Use during the first trimester of pregnancy is not recommended unless considered essential. Use in the second and third trimesters is generally considered acceptable. Use while breastfeeding is acceptable, given minimal systemic absorption.

---

Official Eligibility Statements

Official regulatory documents define eligibility primarily by establishing an absolute prohibition based on allergic history. Conditional restrictions are set related to age and pregnancy status. Use is generally permitted for adults, while the pediatric population and women in early pregnancy require specific consideration or physician evaluation, reflecting the official limitations on use.

Interactions with other medicines and products

Official regulatory information for Antifungol (Clotrimazole) documents interactions that are dependent on the medication’s formulation, focusing on physical incompatibility and systemic pharmacokinetic alterations.

Administration Restrictions and Timing Rules

Substance / Product	Interaction Type	Restriction / Timing Rule
Latex Contraceptives (Condoms, Diaphragms)	Physical Incompatibility	Topical or vaginal formulations may damage the latex material, reducing the contraceptive’s effectiveness. Alternative non-latex precautions are required during treatment and for at least five days following treatment cessation.

---

Systemic Drug Interactions (Oral Form)

Pharmacokinetic interactions are documented for the active ingredient when administered in its systemically available oral formulation (troches/lozenges). Co-administration with certain immunosuppressive medicines, specifically Tacrolimus and Sirolimus, may cause a significant increase in the plasma concentration and blood levels of these drugs.

This outcome is attributed to a pharmacokinetic mechanism involving the inhibition of intestinal CYP3A4 and potentially P-glycoprotein efflux.

Official documentation also notes that no antagonism or synergism has been reported between the active ingredient and other antifungal medicines such as Nystatin or Amphotericin B. For patients with hepatic impairment receiving the oral formulation, monitoring of liver function is advised due to the potential for altered clearance of the drug.

Antifungol, a representative azole antifungal, acts as an inhibitor targeting the fungal enzyme lanosterol 14alpha -demethylase ( CYP51), a cytochrome P450 enzyme. This enzyme is a biological target essential for the conversion of lanosterol to ergosterol, the principal sterol component of the fungal plasma membrane.

The interaction is a non-covalent, coordinate bond between the azole nitrogen atom and the heme iron within the active site of the CYP51 enzyme. This inhibition disrupts the molecular pathway of ergosterol synthesis. Downstream consequences include a depletion of ergosterol, which compromises the structural integrity and fluidity of the fungal plasma membrane. Simultaneously, toxic 14alpha -methylated sterol precursors accumulate within the fungal cell, further stressing the membrane and interfering with the function of membrane-bound enzymes. The system-level physiological consequence of these intracellular events is the cessation of fungal cell growth and replication.

Antifungol, which contains the active substance clotrimazole, is used according to strict, label-based instructions that vary significantly depending on the approved route of administration. The medicine is officially administered via topical (dermal), vaginal (intravaginal), or transmucosal routes, each utilizing a specific dosage form, such as a 1% cream or 500 mg vaginal tablets.

The required dosing schedule is determined by the application site. For topical use on the skin, a thin film of cream is typically applied twice daily—morning and evening. In contrast, vaginal administration often involves a unit dose, such as one tablet inserted once daily, preferably at bedtime. Treatment duration is fixed by the official regimen; for example, application for athlete's foot may require up to four weeks to ensure the full course is completed. Missed doses should generally be applied as soon as they are remembered unless the time is close to the next scheduled dose, in which case the user should skip the missed dose.

Administration involves specific procedural steps. For topical use, the affected skin must be washed and thoroughly dried before the product is gently rubbed in. The labeling also defines minimum age criteria for use; non-prescription topical applications are generally limited to children 2 years of age and older, and vaginal use to those 12 years of age and older. Following these established instructions ensures standardized administration across the approved contexts of use.

Research evidence / Overview of studies for Antifungol

Evidence for Topical Use in Skin Fungal Infections

Antifungol was studied for use in research involving common skin conditions caused by fungal organisms, such as athlete's foot (tinea pedis), ringworm (tinea corporis), and certain yeast infections of the skin (cutaneous candidiasis). Research examined this application primarily utilizing Randomized Controlled Trials (RCTs) and controlled clinical studies. These trials were designed to explore how symptoms change over time, focusing on two key outcomes: whether the fungus could no longer be detected (Mycological Endpoint) and whether the skin signs and patient-reported discomfort showed a measured change (Clinical Endpoint). The studies typically included adults and children who had their infections confirmed by laboratory testing.

Research describes changes measured during the study period. In these controlled settings, studies report how symptoms evolved in the observed populations during the short-term course of treatment, typically lasting two to four weeks. The findings describe the patterns of measured outcomes related to physical discomfort, such as itching, scaling, and redness. These studies contribute to the evidence base that regulators examine when reviewing the data collected on Antifungol to understand how it was studied in the context of these common, superficial fungal and yeast conditions.

The research base for this application exists, but certain limitations are acknowledged, and the evidence quality varies across studies. Long-term outcomes are not well characterized, meaning there is limited information for long-term outcomes on how durable the measured symptom change is or how often the infections return over many months. Furthermore, results apply only to the populations studied, and the data may not fully describe outcomes for individuals with extensive or complex forms of these skin conditions.

---

Evidence for Intravaginal Use in Yeast Infections

The research for Antifungol's intravaginal application was evaluated in women with vulvovaginal candidiasis (VVC), commonly known as a vaginal yeast infection. The primary research base consists of Randomized Controlled Trials (RCTs) and systematic reviews. These studies explored different treatment lengths, such as single-day versus seven-day regimens, and research examined outcomes related to systemic or functional imbalance caused by the infection. The primary measures used in these trials were Mycological Endpoint and Clinical Endpoint, which track the clearance of the Candida fungus and the change in symptoms like itching and irritation.

Clinical trial results from the observed populations data show patterns related to the measured outcomes. Findings from numerous trials evidence suggests that the medicine was observed in these contexts to track the change in acute symptoms and the clearance of the yeast organism at the test-of-cure visit, typically conducted three to four weeks after starting treatment. Systematic reviews of this body of work research describes consistency in the measured outcomes when the infection was associated with the most common causative organism, Candida albicans.

Data are still emerging regarding certain clinical scenarios. For example, evidence is limited regarding the measured outcomes when studying infections caused by less common types of Candida species (non-albicans species). Follow-up durations were limited in the main treatment trials, meaning there is limited information for long-term outcomes regarding the use of Antifungol in research exploring maintenance data. Few data are available for certain groups, such as those with underlying medical conditions like significant immune suppression.

---

Long-term Follow-up and Durability of Study Findings

The majority of pivotal clinical research supporting Antifungol's regulatory status focuses on research exploring short-term symptom changes observed during and immediately after the typical treatment duration (two to four weeks for topical use, one to seven days for intravaginal use). Studies monitored these responses over defined time intervals.

While research describes changes measured during the study period, the follow-up durations were limited in most of the core regulatory trials. Consequently, research exploring maintenance data or durability of effect is not as extensive. Long-term effects are not fully established, and there is limited information for long-term outcomes tracking the stability of the measured change or the frequency of reinfection over many months or years.

---

Evidence in Specific Patient Populations

Antifungol was evaluated in research that included certain populations beyond the general adult population. Specific studies were conducted to examine outcomes in children with superficial skin fungal infections, and research also monitored the use of the medicine in studies focusing on episodes where symptoms become more noticeable in pregnant women for vulvovaginal candidiasis.

These studies help show what has been observed so far in these specific groups. However, for other special groups, such as older adults with multiple health conditions or individuals with underlying chronic health issues, data for certain groups remain insufficient, and the sample sizes were modest in some of the subgroup analyses. Research provides context but not individual predictions, and the results apply only to the populations studied in those clinical trials.

---

Key Research Gaps and Areas of Uncertainty

The research landscape provides considerable insight into the short-term use of Antifungol for common infections, but certain questions remain.

The evidence quality varies across studies concerning certain treatment regimens, and comparative evidence is lacking in some less common scenarios. For the intravaginal use, research focusing on episodes where symptoms become more noticeable in the context of non-albicans Candida species are still being explored, meaning certainty remains low in this specific area.

Overall, the follow-up durations were limited in many pivotal trials, and long-term effects are not fully established, particularly concerning the prevention of future occurrences. Research provides insight into short-term changes, but the subgroup findings are uncertain when looking at outcomes in high-risk patients with specific immune system challenges.

Key Studies & References

1. Clotrimazole: WHO Model List of Essential Medicines
2. Topical antifungal agents for treating tinea pedis (athlete's foot)
3. Drug Monograph: Clotrimazole for Oromucosal and Topical Use (Health Canada)

Common questions about Antifungol (FAQ)

---

Q: How long does it take for Antifungol to start working and for symptoms to improve?

Regulatory information indicates that improvement in symptoms, such as itching and soreness, may be observed within a few days of beginning treatment. Official labeling for certain uses suggests that if symptoms do not improve within the specified period (for example, four weeks for athlete's foot), consulting a healthcare provider may be necessary.

---

Q: What should I do if the fungal infection comes back after I finish my treatment?

Official guidance states that if symptoms of a vaginal yeast infection return within two months after completing the treatment, or if the initial symptoms persist, a healthcare provider should be consulted. According to the product information, this is advised because recurrent or persistent symptoms may necessitate a specialist's evaluation.

---

Q: Does Antifungol expire, and how do I know when to stop using it?

Antifungol has a defined expiration date, which is typically found on the carton and on the product container; unused medication is intended to be disposed of after this date. Official labeling states that use should be discontinued and a healthcare provider should be consulted if the infection persists beyond the labeled duration or if symptoms worsen during treatment.

Storage and Disposal Requirements for Antifungol (Clotrimazole)

Official regulatory labeling dictates specific conditions for storing and disposing of Antifungol to maintain its stability and effectiveness.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze or expose to excessive heat.
Protection	Keep the medicine out of the sight and reach of children. Must be protected from light and moisture.
Container	Store in the original container and keep the closure tightly closed.

Disposal Instructions

Unused or expired Antifungol should be managed through an official drug take-back program if available. Alternatively, the medicine may be mixed with an undesirable substance, sealed in a bag, and disposed of in household trash; it must not be thrown into wastewater (e.g., sink or toilet).